Start your patients

on a convenient,

once daily treatment

Start your patients

on a convenient,

once daily treatment

Start your patients

on a convenient,

once daily treatment

1 / 3

VERQUVO provides a straight forward dose adjustment schedule to achieve the desired 10mg target dose.

  • Start at 2.5mg once daily taken with food.
  • Double dose approximately every 2 weeks, as tolerated.
  • Until the target maintenance dose of 10mg once daily is achieved.
  • Dose adjustment can be achieved in four weeks, but for some patients up-titration may take longer.

90% of patients in the VICTORIA study who received VERQUVO achieved the target dose of 10mg.

Importantly, no dosage adjustment of VERQUVO is required for patients with renal impairment (eGFR ≥ 15 mL/min/1.73m
2
, without dialysis).

This means, VERQUVO can provide a solution for patients who have experienced a worsening heart failure (HF) event and can be used across a broad range of patients with chronic HF, regardless of background therapies.

Verquvo_Website_StartingVerquvo_Graphic_Updated

Remember, after a worsening HF event, patients deteriorate further and need your urgent attention.

A safety profile you can depend on

Adopt a treatment with a well-tolerated safety profile that can be used across a broad range of patients with chronic HF, regardless of background therapy.

Are you worried about hypotension?

Does your patient with Type 2 Diabetes have impaired renal function or other comorbid conditions?

VERQUVO is well tolerated in patients with chronic HF following a worsening HF event.

  • Patients experienced a low rate of symptomatic hypotension. The rates are comparable to placebo (VERQUVO 9.1% vs. Placebo 7.9%).
  • Consistent safety profile in patients with Type 2 Diabetes, impaired renal function (eGFR > 15mL/min/1.73m2), atrial fibrillation and coronary heart disease, as well as in patients who have been treated with other HF therapies.
  • Almost 95% of patients stayed on the therapy throughout the study duration.
  • Discontinuation rates: VERQUVO 6.8% vs. placebo 6.1%.

Especially after a worsening HF event, patients need your protection.

Verquvo® delivered a safety profile comparable to the placebo arm

Verquvo_Placebo